How to Preserve Fertility in Reproductive-Age Women with Cancer

Area of Science:

• Reproductive Endocrinology
• Oncology
• Gynecology

Background:

• Gonadotoxic cancer treatments (chemotherapy, radiotherapy) can impair ovarian reserve and function, leading to premature ovarian insufficiency (POI) and sterility.
• Increasing survival rates in young female cancer patients highlight the critical need for fertility preservation (FP) as part of comprehensive cancer care.
• FP decisions involve patient age, ovarian reserve, treatment type, and gonadotoxic potential.

Purpose of the Study:

• To review current fertility preservation (FP) strategies for young women undergoing gonadotoxic cancer treatments.
• To discuss the clinical applications and limitations of existing FP techniques.
• To explore future directions and research needs for optimizing reproductive outcomes.

Main Methods:

• Review of current literature on fertility preservation techniques in oncology.
• Analysis of established and emerging FP strategies, including oocyte, embryo, and ovarian tissue cryopreservation, and in vitro maturation (IVM).
• Discussion of factors influencing FP decision-making and challenges in clinical practice.

Main Results:

• Oocyte and embryo cryopreservation are established FP methods.
• Ovarian tissue cryopreservation and IVM offer alternatives for patients unable to undergo ovarian stimulation.
• Challenges persist in timely counseling, equitable access, and optimizing long-term reproductive success.

Conclusions:

• Fertility preservation is crucial for young female cancer survivors.
• Advancements in FP offer viable options, but ongoing research is needed to refine techniques and address access barriers.
• Improving reproductive outcomes requires continued innovation and ethical consideration in FP decision-making.